Your browser doesn't support javascript.
loading
RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.
Bigenwald, Camille; Haddad, Yacine; Thelemaque, Cassandra; Carrier, Agathe; Birebent, Roxanne; Ly, Pierre; Flament, Caroline; Lahmar, Imran; de Sousa, Eric; Maeurer, Markus; Miyara, Makoto; Assi, Tarek; Castilla-Llorente, Cristina; Willekens, Christophe; Fayemi, Céline; Lazarovici, Julien; Marabelle, Aurélien; Derosa, Lisa; Ribrag, Vincent; Zitvogel, Laurence.
Afiliação
  • Bigenwald C; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Haddad Y; Hematology Department, Gustave Roussy Cancer Campus, Villejuif, France.
  • Thelemaque C; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Carrier A; Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Birebent R; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Ly P; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Flament C; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Lahmar I; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • de Sousa E; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Maeurer M; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Miyara M; Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Assi T; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Castilla-Llorente C; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Willekens C; Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Fayemi C; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Lazarovici J; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Marabelle A; Université Paris-Saclay, Gustave Roussy, Villejuif, France.
  • Derosa L; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
  • Ribrag V; Institut National de la Santé Et de la Recherche Médicale (INSERM) U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France.
  • Zitvogel L; Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, France.
Oncoimmunology ; 12(1): 2163785, 2023.
Article em En | MEDLINE | ID: mdl-36632566
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Neoplasias Hematológicas / COVID-19 / Mieloma Múltiplo Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / Neoplasias Hematológicas / COVID-19 / Mieloma Múltiplo Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França